Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer. Uppsala, Sweden, February 19, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, have since 2016 been conducting a, pharmacokinetic cross-over clinical phase I … [Read more...]

Bone Therapeutics SA completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Press release Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB® Efficacy and safety results expected in mid-2019 Promising interim efficacy and safety data already reported Gosselies, Belgium, 19 February 2018, 7am CET - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing … [Read more...]

MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California

LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the completed SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS), … [Read more...]

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program. … [Read more...]

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of ANB020, AnaptysBio’s wholly-owned anti-IL-33 antibody program, in adult patients with … [Read more...]